Columnist Sam Kirton had to make some adjustments after his IPF diagnosis, but there are still plenty of ways to find joy, he says.

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

Columnist Sam Kirton marks four years since his bilateral lung transplant by reflecting on his health, his family, and his ...

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

One of my frustrations as a pulmonary fibrosis patient is finding solid information about what to expect as my PF progresses. I’ve asked several doctors what to expect during the end stage of PF, but ...

A study found 10 IPF patients given EGCG, a green tea antioxidant, for 14 days had normal levels of pro-fibrotic proteins in lung tissue.

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...

In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two clinical trials.

The U.S. Food and Drug Administration has granted Bristol Myers Squibb’s investigational therapy BMS-986278 breakthrough therapy status.

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...